On May 1, 2025 Foresight Diagnostics, Inc. ("Foresight"), a leading diagnostics company specializing in the development of ultra-sensitive minimal residual disease (MRD) detection, reported that new data in newly diagnosed diffuse large B-cell lymphoma (DLBCL) will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting taking place from May 30 – June 3, 2025, in Chicago, Illinois (Press release, Foresight Diagnostics, MAY 1, 2025, View Source [SID1234652460]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will deliver an oral presentation in collaboration with Amsterdam University Medical Centers (Amsterdam UMC), highlighting new validation results using Foresight CLARITY MRD, along with a trial-in-progress poster on the SHORTEN-ctDNA clinical trial in partnership with Columbia University. Foresight CLARITY’s ultra-sensitive MRD detection is powered by Foresight’s proprietary PhasED-Seq technology, which delivers an analytical sensitivity of less than 1 part per million in B-cell lymphoma.1

"These presentations mark important clinical validation milestones for our Foresight CLARITY platform," said Dr. David Kurtz, Chief Medical Officer at Foresight Diagnostics. "The presentations demonstrate that our ultra-sensitive MRD detection at the end of first-line therapy identifies DLBCL patients at significantly higher risk of relapse. Meanwhile, the SHORTEN-ctDNA study is exploring how MRD testing can inform de-escalation strategies in newly diagnosed patients. Our goal is to provide oncologists with actionable data that meaningfully improves treatment decisions and patient outcomes."

Further information about the presentations is below:

Oral Presentation Details:

Title: Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial
Presenter: Steven Wang, MD, PhD (Amsterdam UMC)
Session: Oral Abstract Session – Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Time: Friday, May 30 | 2:45 – 5:45 p.m. CDT
Location: Room S100a or live stream for virtual attendees
Abstract number: 7000
Poster Presentation Details:

Title: Sequencing-guided Chemotherapy Optimization Using Real-Time Evaluation in Newly Diagnosed DLBCL With Circulating Tumor DNA: SHORTEN-ctDNA (NCT06693830)
Presenter: Stephanie Meek, PhD (Foresight Diagnostics)
Session: Poster Session – Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Time: Sunday, June 1 | 9:00 a.m. – 12:00 p.m. CDT
Abstract number: TPS7096
Poster Board number: 272a
In addition, the Foresight Diagnostics booth is located in the Innovation Hub #3. To learn more about Foresight’s activities at ASCO (Free ASCO Whitepaper), please visit the ASCO (Free ASCO Whitepaper) event page on our website.

On April 30, 2025 Starpharma, an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient, reported its Quarterly Activities Report and Appendix 4C for the quarter ended 31 March 2025 (Q3 FY25) (Press release, Starpharma, APR 30, 2025, View Source [SID1234654130]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Starpharma’s Chief Executive Officer, Cheryl Maley, commented:
"It is almost 12 months since we announced our revised strategy. We have made significant progress towards achieving our objectives during this time, and we acknowledge that some outcomes are taking longer than we initially anticipated. The Starpharma team remains intensely focused on delivering on our strategic priorities, and we are committed to achieving the outcomes agreed with the Board in May 2024 with a high sense of urgency. Earlier this month, the Board and Leadership team convened to reflect on Starpharma’s progress and to reaffirm our strategic direction going forward

"Our top priorities this quarter have been to advance existing and potential new partnerships, develop the clinical program for DEP SN38 to get to market in the most time- and commerciallyeffective way and build robust pre-clinical data in our radio program that exemplifies the benefits of our dendrimer technology in radiopharmaceuticals.

"The dual goals of our radio program over the past months have focused on creating valuable preclinical data for the development of further enhanced HER2 assets and compelling data for potential partners interested in the application of the DEP platform to radiopharmaceuticals. This will delay the commencement of our clinical program; however, we are excited about the data generated thus far and the potential opportunities to partner in this area.

"This past quarter, we also launched new promotions for Viraleze in the UK and developed a program to make VivaGel BV available online in Europe in FY26.

"We continue managing costs effectively through clear prioritisation, resource management and implementing cost-saving strategies, whilst focusing on revenue generation opportunities such as partner licensing of the DEP platform and assets and product sales for Viraleze and VivaGel BV. We are also enhancing efficiency in drug development by leveraging outsourcing, automation, and exploring the use of AI.

"Whilst the past few months have been challenging across many sectors, including the Australian Biotech sector, we are confident that our versatile platform drug delivery technology offers multiple opportunities for value generation through partnerships and innovative asset development, which we aim to maximise through our strategic priorities.

"I would like to thank our shareholders for your patience and ongoing support as we work diligently to restore value to Starpharma investors."

On April 30, 2025 NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, reported the presentation of full results from the completed dose escalation and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) in patients with locally advanced or borderline resectable pancreatic cancer (Press release, Nanobiotix, APR 30, 2025, View Source [SID1234652390]). The study, conducted by The University of Texas MD Anderson Cancer Center, will be presented by principal investigator Dr. Eugene Koay on Sunday, May 4th at 11:00 AM EDT / 5:00 PM CEST during the 2025 Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO 2025).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PRESENTATION #E25-2265: NANORAY Pancreas: A Phase 1 Study of NBTXR3 (JNJ-1900) Activated by Radiotherapy for Locally Advanced or Borderline Resectable Pancreatic Cancer (LAPC or BRPC)
Koay EJ, Liu S, Guerrero P, Stokes E, Katz MHG, Ikoma N, Snyder RA, Tzeng CD, Overman MJ, Pant S, Wolff RA, Javle M, Holliday EB, Ludmir EB, Das P, Noticewala S, Koong AC, Tamm EP, Bhutani M

Nanobiotix ConferenceCall

Nanobiotix will host a conference call and webcast featuring Nanobiotix chief executive officer and chairman of the executive board, Laurent Levy, to discuss the data on Monday May 5th, 2025, at 8:00 AM EDT / 2:00 PM CEST.

Details for the call are as follows:

Webcast link: click here

Audio-only dial-in link: click here

Participants can use the audio-only link above to register and obtain dial-in instructions to listen to the presentation via phone and ask questions during the Q&A session, or participants can use the webcast link to register and listen and watch the slide presentation online; the replay version will be available under the same webcast link shortly after the presentation and will be archived on the Company’s website at www.nanobiotix.com. It is recommended to join 10 minutes prior to the event start. Participants are invited to email their questions in advance to [email protected].

About JNJ-1900 (NBTXR3)

NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. Its proof-of-concept was achieved in soft tissue sarcomas for which the product received a European CE mark in 2019. The product candidate’s physical mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.

Radiotherapy-activated NBTXR3 is being evaluated across multiple solid tumor indications as a single agent or in combination with anti-PD-1 immune checkpoint inhibitors, including in NANORAY-312—a global, randomized Phase 3 study in locally advanced head and neck squamous cell cancers. In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy—the same population being evaluated in the Phase 3 study.

Given the Company’s focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating NBTXR3 across tumor types and therapeutic combinations. In 2023, Nanobiotix announced a license agreement for the global co-development and commercialization of NBTXR3 with Janssen Pharmaceutica NV, a Johnson & Johnson company.

On April 30, 2025 Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, reported that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at the Citizens Life Sciences Conference taking place in New York City on Wednesday, May 7, 2025 beginning at 3:30 p.m. Eastern Time (Press release, Quince Therapeutics, APR 30, 2025, View Source [SID1234652391]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be accessible on the Events page under the News & Events heading of Quince’s Investor Relations website at ir.quincetx.com. An archive of the webcast will be available shortly following the end of the live event.

On April 30, 2025 Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, reported that the company will explore a full range of strategic alternatives to advance its promising platform and radiopharmaceutical drug development pipeline to maximize stockholder value (Press release, Cellectar Biosciences, APR 30, 2025, View Source [SID1234652361]). Strategic alternatives under consideration may include, but are not limited to mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions. The company’s board of directors has approved the engagement of Oppenheimer & Co. Inc. to serve as exclusive financial advisor to assist in the strategic evaluation process.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have initiated a process to explore alternatives available to the company to maximize stockholder value that includes identifying a strategic partner with the resources to develop iopofosine I 131. In addition to iopofosine I 131, our platform provides exciting opportunities including our alpha- and Auger-emitting radioconjugates, CLR 225 and CLR 125, respectively, in multiple solid tumor indications as well as our small molecule and oligonucleotide conjugates," said James Caruso, president and chief executive officer of Cellectar.

The company has not set a timetable for completion of the strategic evaluation process and does not intend to disclose information on the progress of any such options unless and until it is determined that further disclosure is necessary. No agreement providing for any transaction has been reached and there can be no assurances that any transaction will result from the process of evaluating strategic alternatives. If the process for evaluating strategic alternatives results in an agreement regarding a transaction, there can be no assurances that any transaction will be completed.